What Is Prostatilen? The Registered Prostate Peptide Medicine, Examined
Prostatilen is a registered Russian/CIS prostate-peptide medicine — a bovine-tissue extract, not a synthetic peptide. What the literature actually shows, examined.
Prostatilen is a registered Russian/CIS medicine: a water-soluble peptide fraction ultrafiltered from bovine prostate, sold as injections and rectal suppositories for chronic prostatitis and prostatic hyperplasia. It is unapproved by EMA or FDA, and its clinical evidence is small and regional. This is a literature reference, not a Condor product.
Prostatilen sits in an unusual category: it is not a research chemical and not a designer peptide, but a fully registered pharmaceutical — one that exists on Russian pharmacy shelves with a marketing-authorization number, a manufacturer of record, and roughly three decades of clinical use behind it. It is also almost invisible outside the former Soviet sphere, unrecognized by the EMA or FDA and backed by a literature that is thin, regional, and mostly one language deep. Everything below describes the registered-medicine record and published laboratory and clinical literature, not use in people; nothing here is medical advice or a Condor Research product.
What is Prostatilen, chemically?
Prostatilen is a tissue extract. Specifically, it is a low-molecular-weight, water-soluble peptide fraction obtained by ultrafiltration from the prostate glands of sexually mature bulls.13 That single fact governs almost everything else about how the compound should be read. It is not a synthesized molecule with a defined amino-acid sequence and a CAS number; it is a mixture — a population of peptides co-isolated from an animal organ, defined by its source tissue and manufacturing process rather than by a structural formula. The most recent English-language mechanistic study, from 2025, calls it exactly that, a “substance-mixture,” and contrasts it against Samprost, the corresponding powder substance.9
This is the cleanest line to draw between Prostatilen and the compounds it is often mentioned alongside. The Khavinson-school Cytogen peptides — the short synthetic sequences of the bioregulator program — are defined single molecules. Prostatilen belongs to the older, first generation of that same Russian research lineage: the tissue-extract “peptide bioregulators,” grouped in review literature with Thymalin, Thymogen, Vilon, Epithalamin, and Cortexin.10 The extract is the ancestor; the synthetic short peptides are the descendants. When a supplier lists a CAS number for “Prostatilen,” treat it with suspicion — a batch-defined bovine extract does not have one in the sense a defined chemical does.
~3 mg A 30 mg rectal suppository is labelled as delivering roughly 3 mg of water-soluble peptides — the rest is formulation, not active fraction.
What is actually registered?
The regulatory record is the strongest part of the Prostatilen story, and it is genuine. The Russian drug reference Vidal lists Prostatilen as an actively registered medicine: an injectable lyophilizate whose active substance is “prostate extract” (water-soluble peptides, formulated with glycine), classed pharmacotherapeutically as an agent for the treatment of chronic prostatitis, with the marketing-authorization holder recorded as MBNPK Cytomed.14 It exists in two principal dosage forms — the intramuscular lyophilizate and the rectal suppository, the latter typically a 30 mg dose combined with dimexide (DMSO/Dimexidum) as a penetration enhancer.5
| Attribute | What the record shows |
|---|---|
| Type | Registered medicine (Russia / CIS), not a research chemical |
| Active substance | Prostate extract — bovine, water-soluble peptide fraction |
| Forms | IM lyophilizate (with glycine); rectal suppository ~30 mg (with dimexide/macrogol) |
| Holder | MBNPK Cytomed |
| EMA / FDA status | Not approved |
| Labelled use | Complex therapy of chronic prostatitis, BPH symptoms, post-surgical recovery |
Regulatory framing only. “Registered in Russia/CIS” describes marketing-authorization status in those jurisdictions; it is not an efficacy verdict and carries no EU/US approval.
Prostatilen is also not alone. It sits within a small family of registered Russian prostate-extract drugs — Vitaprost, Uroprost, and the substance-powder Samprost — and manufacturer-adjacent reviews describe it as the first prostatic-peptide bioregulator to enter wide clinical use, with a claimed ~30-year track record dating to isolation in the mid-1980s.13 A later combination, Prostatilen AC (also marketed as Forte), adds zinc arginyl-glycinate and arginine to the peptide complex and is registered separately, aimed at sperm parameters rather than the base prostatitis indication.7,8
Registered is not the same as proven. The marketing authorization is real; the modern independent evidence to match it is not.
What the literature reports it does
The reported mechanisms in the published work are consistent, if modestly evidenced. Studies frame Prostatilen as reducing prostatic oedema and inflammation and improving local microcirculation. A combined animal-and-human study — 120 intact plus 240 prostatitis-model rats alongside 34 patients — examined effects on hemostasis and reported antiplatelet and pro-fibrinolytic actions, which is the origin of the “improves microcirculation” claim that recurs throughout the corpus.6 Later mechanistic work has looked at smooth-muscle contractility, including a 2025 study of contractile activity in rat lymphatic vessels that positioned the extract against the Samprost powder.9
On the clinical side, the debut trials date to 1991, introducing Prostatilen as a bovine-prostate polypeptide preparation for chronic prostatitis and describing anti-inflammatory and immunomodulating effects.1,2 The largest reported patient series is a single-center account of 1,115 patients with chronic pyelonephritis and prostatitis, describing the drug as “pathogenetically sound.”3 BPH-adjacent work includes a review of 96 patients aged 51–89 reporting relief of infravesical obstruction, and a repeated-course suppository study in prostatic adenoma.4,5 The one clearly English-language, randomization-mentioning clinical paper (n=98) tested the zinc-enriched Prostatilen AC and, usefully for the record, states outright that Prostatilen is a “previously registered medicine” of bovine prostate bioregulatory peptides.8
An honest read of the evidence
The registration is solid; the evidence base underneath it is not, and the two should never be conflated. The entire PubMed footprint for Prostatilen is roughly 28 records, and only three of those are in English. The clinical work clusters around a small number of St. Petersburg and Cytomed-affiliated author groups — Al’-Shukri, Gorbachev, Khavinson, Boiko, Kuzmin — which means it is developer-adjacent rather than independently replicated. There is essentially no modern randomized, placebo-controlled trial of Prostatilen itself; the studies are uncontrolled case series and clinic experience from roughly 1991 to 2006. Where “randomized” appears in the literature, it does not consistently attach to base Prostatilen — one of the few randomized hits in this space tests a different bladder peptide entirely, not this drug. Major international bodies do not recognize it: EAU, AUA, and NICE guidance for chronic prostatitis and CPPS, and contemporary meta-analytic reviews of pharmacological interventions, simply do not list Prostatilen as a validated therapy class. The fair description is a regional adjunct, not an international standard.
There is also a genuine safety signal that a balanced account cannot leave out. Two 1990s mouse studies reported that Prostatilen increased sperm-head anomalies and bone-marrow chromosome aberrations — a mutagenicity/genotoxicity signal — with one paper examining whether vitamin C could modify that effect and a companion study testing whether immobilizing the peptide in polyvinyl alcohol reduced it.11,12 That the investigators were actively trying to mitigate the effect tells you the signal was taken seriously at the time. It is old, animal-model data, but it is real published data and it points in an uncomfortable direction for a compound whose newer formulations are marketed around reproductive parameters. Layered on top is the intrinsic problem of any bovine-tissue extract: batch-to-batch variability and animal-origin pathogen-screening concerns, with no standardized Western manufacturing or quality requirement, precisely because the product is unapproved by the EMA and FDA. Much of the mechanistic and clinical corpus is Russian- or Ukrainian-language with limited access to full methods, and several of the most enthusiastic sources — product retailers and manufacturer reviews — are commercial and non-independent. Efficacy claims sourced from those channels, particularly around sexual or reproductive function, should be read as marketing rather than trial outcomes.
Prostatilen is described here strictly as an educational reference. It is a medicine registered in Russia and CIS jurisdictions, unapproved in the European Union and the United States, and it is not offered or supplied by Condor Research. Every finding above is reported as published laboratory or clinical literature — what a study observed in mice, in rats, or in a patient series — not as guidance for use in any person or animal. Nothing on this page is a dosing protocol, a treatment recommendation, a safety assessment, or medical advice.
Condor Research · Wetenschappelijke helpdesk
Atrio Sciences s.r.o., IČO 57 669 651, Nitra (SK) · info@condorresearch.com
- Prostatilen is a genuinely registered pharmaceutical in Russia and CIS countries (e.g. IM lyophilizate RU LP-No.(014379)-(RG-RU)), marketed by MBNPK Cytomed; it is not approved by the EMA or FDA.
- It is a batch-defined biological mixture, not a defined synthetic peptide — a low-molecular-weight water-soluble peptide fraction obtained by ultrafiltration from the prostate glands of mature bulls.
- Because it is an animal-tissue extract there is no single defining CAS number; the label ingredient is 'prostate extract', unlike the single-sequence Cytogen bioregulators.
- Registered indications in those jurisdictions are urological: chronic prostatitis, benign prostatic hyperplasia, and post-surgical recovery, always described as part of complex therapy.
- The PubMed footprint is roughly 28 records, only three in English, clustered around a few St. Petersburg / Cytomed-affiliated author groups — i.e. developer-adjacent, not independent replication.
- A historical mouse-mutagenicity signal exists (increased sperm-head anomalies and bone-marrow chromosome aberrations) that a balanced account should not omit.
- A separate combination, Prostatilen AC (Forte), adds zinc arginyl-glycinate and arginine; it is a distinct registration targeting sperm parameters.
Is Prostatilen a real, registered medicine?
Yes. It holds active Russian marketing authorizations as an intramuscular lyophilizate and as rectal suppositories, with MBNPK Cytomed as the recorded holder. Registration in Russia and CIS states is not equivalent to EMA or FDA approval, and it does not imply an independent Western evidence base.
Is Prostatilen the same kind of thing as the Cytogen peptides?
No, and the distinction matters. The Cytogen line consists of defined, single-sequence synthetic peptides. Prostatilen is a batch-defined bovine-tissue extract — a mixture of peptides isolated from bull prostate by ultrafiltration, not one characterized molecule. They come from the same Russian research lineage but sit at opposite ends of it.
What is it actually used for in the countries where it is registered?
Its labelled indications are urological: chronic prostatitis, benign prostatic hyperplasia symptoms, and post-prostate-surgery recovery, always framed as part of complex therapy rather than a stand-alone cure. This describes registered labelling in those jurisdictions and is not a use recommendation.
Is the evidence strong enough to call it effective?
No. The literature is small — around 28 PubMed records, only three in English — largely uncontrolled, and clustered among a few developer-adjacent St. Petersburg/Cytomed groups. There is no independent Western randomized replication, and international urology guidelines do not list it as a validated therapy.
Is there any safety signal in the literature?
Yes, a historical one. Two 1990s mouse studies reported increased sperm-head anomalies and bone-marrow chromosome aberrations, a genotoxicity signal, with follow-up work attempting to modify or mitigate the effect. It is old animal data, but it is real and worth reporting honestly.
What is Prostatilen AC, and does Condor sell any of this?
Prostatilen AC (Forte) is a separate, later registration that adds zinc arginyl-glycinate and arginine to the peptide complex, studied for sperm parameters. Condor Research does not sell Prostatilen or Prostatilen AC; this page is an educational reference to a registered foreign medicine, not a product listing.